Should you buy Merck & stock now?
Yes, the technical signal for Merck & is currently BUY. Merck & trades at $128.60 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 1.692 with falling momentum (signal: 2.066); RSI is at 54.0 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $135.38 points to 5.3% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Merck & stock?
The average analyst price target for Merck & is $135.38. The current price is $128.60, which gives an upside of 5.3%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $121.84 and $148.92.
Is Merck & a dividend stock?
No, Merck & does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Merck & stock?
Merck & is rated as a stock with moderately low risk. the annual standard deviation is 27.5%, which classifies the stock as moderately low risk.
Is Merck & overvalued?
Merck & is considered fairly valued – the price is close to the analyst price target. Merck & has the following valuation ratios: a P/E ratio of 36.0 (highly valued), a P/S ratio of 4.8, a P/B ratio of 7.0. The stock trades close to the analyst price target and is considered fairly valued.
Is Merck & overbought?
No, Merck & is not overbought. RSI is at 54.0 (neutral zone). The technical indicators show: RSI is at 54.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.9% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Merck & earnings report?
Merck & reports its next earnings on October 29, 2026. The stock currently trades at $128.60. With a P/E ratio of 36.0, the market will be watching closely whether earnings meet expectations.
Is Merck & shorted?
Yes, Merck & is shorted with 1.2% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Merck & stock?
No, insiders are not buying Merck & shares – they are net sellers. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 26,750,202 $ sold. Active sellers include Smart Dalton E. III, Maraldo David R., Larson Betty D and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Merck & a good stock?
Based on our total score, Merck & is rated as a good stock with a total score of 61 out of 100. The stock scores above average on value, quality and momentum – it is among the top 39% in our database. The score is made up of Value: 31/100, Quality: 70/100, Momentum: 83/100. In addition: technical signal: Strong Buy. Whether Merck & is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Merck & stock?
The outlook for Merck & based on current data: the average analyst price target is $135.38 (+5.3%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 10/29/2026, which can move the price; the P/E ratio is 36.0 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Merck & stock moving?
Merck & is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Merck & go?
The average analyst price target for Merck & is $135.38, which corresponds to a potential gain of 5.3% from the current price of $128.60. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Merck & fall?
We lack enough history to give a specific floor for Merck &. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Merck & do?
mrk.us, eller Merck & Co., driver en stor sundhedsvirksomhed globalt. De tjener primært penge på to områder: medicin til mennesker og produkter til dyrehelse. På medicinsiden udvikler og sælger de lægemidler inden for onkologi, som kræftmidlet Keytruda, samt vacciner til både ... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Merck & as an investment.
Did Merck & raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Merck &. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Merck & making money or losing money?
Yes, Merck & is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 13.6% — which is solid. The operating margin (profit before interest and taxes) is 38.6%. At a P/E ratio of 36.0, you currently pay 36.0 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Merck & go bankrupt?
The bankruptcy risk of Merck & is rated as low. Altman Z2 (a model for assessing financial distress) is 3.35 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 153% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Merck & have a lot of debt?
Yes, Merck & has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 153%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Merck & service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is -7.4x, and net debt equals 1.5 years of earnings (EBITDA).
